comparemela.com

Page 8 - Phar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lilly experimental triple G obesity drug leads to 24 2% weight loss in trial

Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.

Factbox: Who is behind the sweeping MOVEit hack?

The cl0p ransomware gang is claiming a new set of victims from its hack of the MOVEit file transfer protocol, taking credit on Tuesday for having stolen data from the University of California, Los Angeles, Siemens Energy , Abbvie Inc and Schneider Electric , among others.

Weight loss drug Wegovy slower to launch in new markets - Novo Nordisk

Novo Nordisk's launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.

Clene s ALS drug shows reduction in disease indicator levels in trial

Clene said on Thursday its experimental amyotrophic lateral sclerosis (ALS) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.